GLP-1 Drug Market Research Report: Size, Share, Trend Analysis By Drug Type (Short-acting, Long-acting, Dual-action), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Type 2 Diabetes, Obesity, Cardiovascular Diseases), By Administration Route (Subcutaneous Injection, Oral, Inhalation) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035 ID: MRFR/HC/20411-HCR 128 Pages Last Updated: May 15, 2026 GLP-1 Drug Market Market Size Forecast Period2025 - 2035 CAGR (2025 - 2035)13.17% 2024 Market Size$ 10.77 Billion 2025 Market Size$ 12.19 Billion 2035 Market Size$ 42 Billion Key Players Companies such as Novo Nordisk Eli Lilly Sanofi Boehringer Ingelheim AstraZeneca Merck & Co
Lancet 397(10278):971984 Shi I, Khan SS, Yeh RW, Ho JE, Dahabreh IJ, Kazi DS (2025) Semaglutide Eligibility Across All Current Indications for US Adults
Key Takeaway: Direct dietary glutathione is often lost during digestion
4.10 Protein and Lean Mass Although not a micronutrient, protein intake is central to nutritional adequacy during GLP-1 therapy
This involves dividing the total daily dose into two or even three smaller administrations spaced throughout the day
